Celcuity (NASDAQ:CELC) has announced the pricing of two underwritten public offerings. The first is a $175 million offering ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Celcuity ( ($CELC) ) has issued an announcement. On July 30, 2025, Celcuity Inc. entered into an underwriting agreement with several underwriters ...

Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public ...

An update from Celcuity ( (CELC) ) is now available.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Celcuity ( (CELC) ) just unveiled an ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Among last week’s news, US biotech Celcuity leapt 180% on new Phase III data for its cancer drug candidate gedatolisib. US drugmaker Madrigal Pharmaceuticals entered into a licensing deal with China’s ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – The average age of cancer patients is getting younger, as experts are ...

Earnings watch - Notable companies due to report include Palantir Technologies ( PLTR ), MercadoLibre ( MELI ), Wayfair ( W ) ...

The algorithm, developed by AI specialist Lunit, was retrospectively tested in conjunction with an advanced 3D mammography ...

At the 2025 Alzheimer’s Association International Conference, one of the bigger splashes was made by an experimental cardiovascular drug. Newamsterdam Pharma Co. NV presented data showing that its ...